{"id":"W3095852744","doi":"10.15326/jcopdf.2020.0158","title":"InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions","year":2020,"lang":"en","type":"article","venue":"Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Sanofi Genzyme; Pearl Therapeutics; Genentech; Grifols; Mylan; Regeneron Pharmaceuticals; Boston Scientific Corporation; Sunovion; Gilead Sciences; Galderma; York University; AstraZeneca; Dartmouth College; Chiesi Farmaceutici; Sanofi; Medical Research Council; Biogen; GlaxoSmithKline; Veracyte; Teva Pharmaceutical Industries; National Heart, Lung, and Blood Institute; American Thoracic Society","keywords":"Medicine; Fluticasone propionate; Dry-powder inhaler; COPD; Inhaler; Internal medicine; Asthma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002572614,0.0006276312,0.001416931,0.0003850722,0.000322907,0.0001062825,0.0006429197,0.0001131118,0.00008207554],"category_scores_gemma":[0.0004091642,0.0003342143,0.0006727437,0.001962202,0.001220421,0.0006180351,0.0003320054,0.0005670343,0.000002680914],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001105022,"about_ca_system_score_gemma":0.0008705409,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000930426,"about_ca_topic_score_gemma":0.0000631288,"domain_scores_codex":[0.995367,0.0007765419,0.00140142,0.0006070526,0.001243255,0.0006047137],"domain_scores_gemma":[0.9954823,0.0005993811,0.001862893,0.0008737894,0.0007212523,0.0004603774],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09499977,0.001886492,0.8696847,0.000327612,0.004364605,0.0001087516,0.001630822,0.0006860294,0.0008211625,0.0000152016,0.00005332891,0.02542154],"study_design_scores_gemma":[0.03403598,0.004776869,0.9524854,0.0004194627,0.003205112,0.0001194527,0.0008271792,0.003011584,0.0002465753,0.00001674843,0.0005545131,0.0003010639],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991107,0.004254816,0.00006164247,0.001159879,0.00032553,0.002410758,0.0005997016,0.00001779357,0.00006281996],"genre_scores_gemma":[0.9976545,0.001651501,0.00002312546,0.0001527727,0.0002044906,0.00004379767,0.0001630039,0.00006893023,0.00003789989],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08280076,"threshold_uncertainty_score":0.999911,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03244249774097455,"score_gpt":0.2780959886263978,"score_spread":0.2456534908854233,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}